Crospon received FDA clearance for expanded indications of use for its EndoFLIP endolumenal imaging system.
Here are four highlights:
1. The system and catheters are now cleared for use in sphincter measurements in patients with such disorders as gastroparesis and fecal incontinence.
2. These new indications expand the use of EndoFLIP beyond the esophagus and stomach.
3. CMS provides payments for the use of EndoFLIP in the esophagus under the CPT code 91040, which became effective Jan. 1, 2016.
4. Founded in 2006 and based in Ireland, Crospon develops minimally invasive medical devices for monitoring, diagnosis and therapy in the areas of minimally invasive surgery and gastroenterology.